Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CYBN NASDAQ:GHRS NASDAQ:OCS NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$6.73+12.5%$7.48$4.81▼$13.88$158.76M0.68345,357 shs754,177 shsGHRSGH Research$14.09+0.3%$14.18$6.00▼$20.50$730.99M0.97195,288 shs245,365 shsOCSOculis$17.22+0.3%$17.85$11.56▼$23.08$749.24M0.2611,177 shs16,386 shsSNDLSNDL$2.48+1.6%$1.83$1.15▼$2.74$641.17M3.925.07 million shs2.69 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin+12.54%-10.03%-9.79%-24.38%+1,723.85%GHRSGH Research+0.28%+4.37%+15.97%+12.72%+66.35%OCSOculis+0.35%+6.76%-5.38%-13.55%+43.62%SNDLSNDL+1.64%-7.46%+46.75%+87.88%+22.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$6.73+12.5%$7.48$4.81▼$13.88$158.76M0.68345,357 shs754,177 shsGHRSGH Research$14.09+0.3%$14.18$6.00▼$20.50$730.99M0.97195,288 shs245,365 shsOCSOculis$17.22+0.3%$17.85$11.56▼$23.08$749.24M0.2611,177 shs16,386 shsSNDLSNDL$2.48+1.6%$1.83$1.15▼$2.74$641.17M3.925.07 million shs2.69 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin+12.54%-10.03%-9.79%-24.38%+1,723.85%GHRSGH Research+0.28%+4.37%+15.97%+12.72%+66.35%OCSOculis+0.35%+6.76%-5.38%-13.55%+43.62%SNDLSNDL+1.64%-7.46%+46.75%+87.88%+22.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYBNCybin 3.25Buy$85.001,163.00% UpsideGHRSGH Research 2.88Moderate Buy$32.00127.11% UpsideOCSOculis 3.00Buy$35.75107.61% UpsideSNDLSNDL 3.00Buy$4.5081.45% UpsideCurrent Analyst Ratings BreakdownLatest CYBN, OCS, SNDL, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025SNDLSNDLAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/22/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $33.008/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$73.00 ➝ $70.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$39.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYBNCybinN/AN/AN/AN/A$10.83 per shareN/AGHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AOCSOculisN/AN/AN/AN/A$1.91 per shareN/ASNDLSNDL$671.81M0.97N/AN/A$3.15 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYBNCybin-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/AGHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)OCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)SNDLSNDL-$69.18M-$0.27N/AN/AN/A-10.38%-8.58%-7.23%11/4/2025 (Estimated)Latest CYBN, OCS, SNDL, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/A7/31/2025Q2 2025SNDLSNDL-$0.04$0.01+$0.05$0.01$231.50 million$179.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYBNCybinN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYBNCybinN/A24.2424.24GHRSGH ResearchN/A29.4929.49OCSOculis0.014.554.55SNDLSNDL0.115.033.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYBNCybin17.94%GHRSGH Research56.90%OCSOculis22.30%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipCYBNCybin15.00%GHRSGH Research41.60%OCSOculisN/ASNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYBNCybin5023.59 million17.96 millionNot OptionableGHRSGH Research1052.03 million30.38 millionOptionableOCSOculis243.66 millionN/ANot OptionableSNDLSNDL2,516262.78 millionN/AOptionableCYBN, OCS, SNDL, and GHRS HeadlinesRecent News About These CompaniesInvesco Ltd. Sells 189,516 Shares of SNDL Inc. $SNDLSeptember 6 at 3:08 AM | marketbeat.comSNDL (NASDAQ:SNDL) Shares Gap Up - Should You Buy?September 5 at 11:37 AM | marketbeat.comSNDL (NASDAQ:SNDL) Earns Buy Rating from Analysts at Alliance Global PartnersSeptember 5 at 8:25 AM | marketbeat.comSNDL (NASDAQ:SNDL) Trading Down 6.2% - Should You Sell?September 4 at 1:47 PM | marketbeat.comAlliance Global Partners Initiates Coverage of SNDL (SNDL) with Buy RecommendationSeptember 4 at 3:15 AM | msn.comSNDL initiated with a Buy at Alliance Global PartnersSeptember 3 at 3:16 PM | msn.comMichigan Cannabis Retailer Case Ruling Codifies Receiver PowerAugust 29, 2025 | news.bloomberglaw.comNHow’s the Market Reacting to SNDL Inc’s (SNDL) Q2 Results?August 29, 2025 | finance.yahoo.comSNDL (NASDAQ:SNDL) Sets New 1-Year High - Time to Buy?August 28, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Trading Up 6.4% - Should You Buy?August 27, 2025 | marketbeat.comWhat Makes SNDL Inc. (SNDL) a Strong Momentum Stock: Buy Now?August 27, 2025 | zacks.comSNDL Inc. (SNDL)'s Technical Outlook is Bright After Key Golden CrossAugust 27, 2025 | zacks.comDespite Fast-paced Momentum, SNDL INC (SNDL) Is Still a ... - NasdaqAugust 23, 2025 | nasdaq.com3 Top Canadian Marijuana Stocks Impacted By The Cannabis IndustryAugust 22, 2025 | marijuanastocks.comMDespite Fast-paced Momentum, SNDL INC (SNDL) Is Still a Bargain StockAugust 21, 2025 | zacks.comSNDL (NASDAQ:SNDL) Trading 5.2% Higher - What's Next?August 20, 2025 | marketbeat.comForm 13G SNDL Inc. For: 14 AugustAugust 14, 2025 | investing.comSNDL (NASDAQ:SNDL) Sees Strong Trading Volume - Here's What HappenedAugust 13, 2025 | marketbeat.comTop Canadian Marijuana Stocks If Federal Reform Passes In The USAAugust 13, 2025 | marijuanastocks.comMInvestors Buy Large Volume of SNDL Call Options (NASDAQ:SNDL)August 13, 2025 | marketbeat.comExplainer-How US Marijuana Reclassification Could Help Cannabis CompaniesAugust 12, 2025 | usnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, OCS, SNDL, and GHRS Company DescriptionsCybin NYSE:CYBN$6.73 +0.75 (+12.54%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.56 -0.17 (-2.45%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.GH Research NASDAQ:GHRS$14.09 +0.04 (+0.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.71 -0.38 (-2.69%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Oculis NASDAQ:OCS$17.22 +0.06 (+0.35%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$17.26 +0.05 (+0.26%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.SNDL NASDAQ:SNDL$2.48 +0.04 (+1.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.46 -0.02 (-0.60%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
